Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Regeneus Ltd. ( (AU:CMB) ) has provided an update.
Regeneus Ltd. has announced the cessation of Graham Vesey as a director of Cambium Bio Limited, effective November 22, 2024. This update includes details of Vesey’s interests in the company’s securities, which comprise 147,711 fully paid ordinary shares and 10,295 unlisted options. This change in directorship is part of the company’s compliance with ASX listing rules and the Corporations Act, potentially affecting its governance structure and signaling a shift in its management approach.
More about Regeneus Ltd.
YTD Price Performance: -5.00%
Average Trading Volume: 10,548
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$5.37M
See more insights into CMB stock on TipRanks’ Stock Analysis page.